Repligen expands course of analytics portfolio with DRS daylight options settlement

Repligen Company, a life sciences firm centered on bioprocessing expertise management, right this moment introduced it has entered right into a strategic partnership and unique license settlement with DRS Daylight Options to increase using mid-infrared (mid-IR) expertise within the bioprocessing market.

By way of this settlement, Repligen will assume accountability for the commercialization of Culpeo®, in addition to the event of future merchandise and applied sciences in partnership with DRS Daylight Options (“Daylight”). Each firms will concentrate on increasing the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) primarily based options and integrating these options into Repligen Chromatography and Filtration techniques to increase the businesses’ presence within the fast-growing Course of Analytics Know-how (PAT) section of the bioprocessing market.

Daylight’s patented QCL-IR expertise measures increased order protein and nucleic acid construction, facilitating the measurement of protein aggregation, focus and nucleic acid content material and different essential attributes in organic manufacturing processes. Correct readouts can be found in seconds, enabling real-time course of monitoring in upstream and downstream manufacturing.

San Diego-based Daylight specializes within the growth and manufacturing of modern options primarily based on its QCL expertise platform, which operates all through the mid-IR spectral vary. Daylight, identified for best-in-class merchandise supporting business, analysis, and aerospace and protection markets, entered the bioprocessing market in 2018 with its ground-breaking Culpeo® instrument.

We’re delighted to have signed this settlement with DRS Daylight Options, which enhances our current analytics portfolio from C Applied sciences, a pioneer in real-time, in-line course of monitoring options. We consider that the Daylight portfolio will serve to speed up and increase adoption of in-line course of monitoring within the bioprocessing trade. We look ahead to working with Tim Day and the group at Daylight.”

Tony J. Hunt, CEO, Repligen

We’re very excited to companion with Repligen to make QCL-IR primarily based options a game-changing expertise in PAT. We consider Repligen is the most effective companion to perform this, given their success with C Applied sciences and their observe document of innovation in bioprocessing. We look ahead to working along with Tony Hunt and the Repligen group to supply bioprocessing prospects this ground-breaking expertise to measure essential course of parameters in biologics manufacturing. With real-time and excessive reliability outcomes, Culpeo® will finally enhance manufacturing yields, scale back prices and guarantee product high quality.”

Dr. Timothy Day, Senior Vice President and Normal Supervisor, DRS Daylight Options

Source

Share

Leave a Reply